SINGAPORE, Sept. 30, 2024 /PRNewswire/ -- CHARLES & KEITH continues its remarkable global expansion, reinforcing its status as a leading fashion brand by opening three standout flagship stores in major cities across Asia in 2024, following its inaugural flagship concept debut in Seoul the previous year. As the brand grows internationally, it remains committed to merging timeless design with modern retail experiences. Each flagship represents a strategic milestone in its global journey and integrates local culture with the brand's signature minimalist elegance.
The first opening of 2024, in March, saw the brand partner with the internationally acclaimed architectural firm, David Chipperfield Architects Milan, for a one-of-a-kind Maison in the vibrant district of Shibuya Center-Gai, Tokyo. Constructed in partnership with and with a design ethos characterized by sobriety and elegance, the retail space holds a special significance and is both essential and dynamic, embodying the brand's evolution from humble beginnings to a modern, classic fashion icon. The duplex boutique is a sculptural space for fashion and defined by a distinctive lime-based plaster membrane outlining a sequence of pink resin niches that maximize the retail space's geometry precision. Floors in semi-polished reconstructed stone generate a contrast with the roughness of the walls, and modular solutions and adaptable furnishings are easily implemented in various locations of the store, maintaining a seamless blend of elegance and contemporary aligned with the brand's identity.
The brand's third global flagship — its first in its home city — opened its doors barely four months later. Located at the iconic Jewel, Changi Airport, the boutique pays homage to Singapore's unique identity, blending elements of traditional architecture, lush greenery and urban sophistication into a distinctive retail experience. Inspired by the vibrant essence of Singapore, the store's concept is a tribute to courtyards of old shophouses and the verdure landscapes that define the little red dot. Customised island displays, uniquely shaped to reflect the island's topography, highlight the latest shoe collections, and a central space, sheltered by a large, curved LED glass panel serves as a striking focal point and displays a rich tapestry of breathtaking and compelling videos of nature in Singapore, marking the boutique as an immersive experiential store at the forefront of visual storytelling.
This month at MixC Chengdu, the brand has revealed its largest global boutique to date, which stands as a testament to the brand's commitment to elevating its retail experience and strengthening its presence in the Asian market. Spanning two storeys with a total area of 564 square metres, the breathtaking duplex reflects the clean-lined, minimalist aesthetic of the brand and was meticulously designed in a palette of soothing neutral hues. Chengdu-exclusive features were also integrated into the store such as Chinese artist Zhao Wei's commissioned art piece, 'Good time', a depiction of a calm yet vibrant scene highlighting the laidback versatility of the iconic Charlot bag, to honour the local culture and provide a one-of-a-kind shopping experience. The store's exterior is adorned with lush greenery and stone-like seating, reminiscent of a tranquil zen garden, redefining the traditional concept of a store façade and provides shoppers with a uniquely serene respite from the bustle of the city.
The three flagship stores reflect CHARLES & KEITH's ongoing commitment to offering an elevated, immersive shopping experience as the brand continues its expansion and innovative spirit.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
CHARLES & KEITH EXPANDS HORIZONS, OPENING THREE DISTINCTIVE FLAGSHIP STORES IN KEY GLOBAL CITIES WITHIN SIX MONTHS
CHARLES & KEITH EXPANDS HORIZONS, OPENING THREE DISTINCTIVE FLAGSHIP STORES IN KEY GLOBAL CITIES WITHIN SIX MONTHS
CHARLES & KEITH EXPANDS HORIZONS, OPENING THREE DISTINCTIVE FLAGSHIP STORES IN KEY GLOBAL CITIES WITHIN SIX MONTHS
HONG KONG, Sept. 30, 2024 /PRNewswire/ -- GenEditBio Limited ("GenEditBio"), a biotech company co-founded by Prof. ZHENG Zongli from the City University of Hong Kong that focuses on precision genome editing to provide affordable "precision DNA surgery" for genetic diseases with unmet needs, is pleased to have AEF Greater Bay Area Fund, managed by Gobi Partners GBA, a leading venture capital firm in Asia, invested in our company. The investment will be used to further develop and enhance our editing and delivery technologies, to advance our in vivo programs, as well as to initiate clinical studies for safety and efficacy.
"We are excited to partner with Gobi Partners GBA and leverage on their rich experience in nurturing start-ups into successful businesses," said ZHENG Zongli, PhD, Co-Founder and Chairman of GenEditBio. "This investment will allow us to cultivate our talent pool, accelerate our research engine and transform our cutting-edge genome-editing and drug delivery technologies to life-changing therapeutics to those in desperate need."
"This investment will enable us to stay at the forefront of genome editing as well as novel delivery and advance our multiple pipeline programs towards clinical studies," said ZHU Tian, PhD, Co-Founder and CEO of GenEditBio. "We are grateful for such strong support. Their extensive network of public and private sector partners and expertise in the biotech industry will be invaluable to realise our ambitious goals as we continue to innovate and excel."
"We are proud to be supporting GenEditBio's work in genome editing," said Chibo TANG, Managing Partner of Gobi Partners GBA. "We believe their innovative approach could lead to significant advancements in the field and we are excited about the potential of their technology to contribute to scientific progress and patient care. We very much look forward to working with them to make that vision a reality."
About the In Vivo Programs
GEB-100 and GEB-200 programs based on proprietary lipid nanoparticles (LNPs) delivery
targeting the liver have completed proof-of-concept studies in non-human primates and are
on-track to nominate drug candidates in the third quarter of 2024. GEB-400 program
targeting an inherited retinal disease is expected to achieve drug candidate nomination in
2024 and enter clinical stage in 2025, which will showcase the company's next-generation
delivery technology, named ePDVs (engineered protein delivery vehicles).
About GenEditBio
Established in 2021 and headquartered in Hong Kong, China, GenEditBio is a gene therapy start-up company with an overarching strategic goal of providing potentially curative, once-and-done and programmable in vivo genome editing-based therapeutic solutions (dubbed "DNA surgery") with high safety profile, unmatched precision, and affordable access for genetic diseases that currently lack cures or effective treatments. The Company's core areas of focus include novel Cas nuclease discovery and safe and efficient cargo delivery utilizing LNPs and ePDVs. We have research laboratories and supporting offices in Hong Kong, Beijing, and Boston. GenEditBio is financially backed by top-tier life science investors, including Qiming Venture Partners, Fangyuan Capital, Center Ventures, Lumosa Therapeutics, Innovation and Technology Venture Fund of the HKSAR Government, and HKSTP Venture Fund.
About Gobi Partners GBA (Gobi GBA)
Gobi Partners GBA (Gobi GBA) was established in 2016 as a part of the leading Pan-Asian venture capital platform Gobi Partners. Gobi GBA is the general partner of the Alibaba Hong Kong Entrepreneurs Fund, L.P. (AEF) as well as the AEF Greater Bay Area Fund LPF, and has formed strategic partnerships with other renowned financial institutions such as HSBC and Hang Seng Bank. As of 2023, Gobi GBA has invested in over 80 startups across the Greater Bay Area and has fostered the growth of 8 unicorns including Airwallex, Amber, Animoca Brands, GoGoX, Prenetics, and more.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
GenEditBio Secures Strategic Investment from Gobi Partners GBA to Accelerate Breakthrough Genome Editing Technologies
